We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aeterna Zentaris Inc | NASDAQ:AEZS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.115 | -1.33% | 8.53 | 8.51 | 8.68 | 8.80 | 8.3754 | 8.46 | 11,446 | 20:27:02 |
NEW YORK, Jan. 9, 2015 /PRNewswire/ -- Levi & Korsinsky announces that the class period for a case commenced on behalf of Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company") (Nasdaq: AEZS) shareholders has expanded to include shareholders who purchased shares between April 2, 2012 and November 6, 2014.
For more information, click here: http://zlk.9nl.com/aeterna-zentaris.
The complaint alleges that Aeterna Zentaris misstated information about its New Drug Application ("NDA") with the FDA for the drug MACRILEN. On October 18, 2012, the Company announced Phase III clinical trial results for MACRILEN, noting that the results "confirm [the drug's] potential as possibly the first approved oral diagnostic test for" ADHD. These trials were conducted pursuant to a Special Protocol Assessment that was agreed upon with the FDA.
On November 6, 2014, however, it was revealed that the FDA would not approve the NDA in its present form, noting that the "trial did not meet its stated primary efficacy objective as agreed to in the Special Protocol Assessment agreement letter between the Company and the FDA."
If you suffered a loss in Aeterna Zentaris you have until January 12, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/aeterna-zentaris.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits and have helped shareholders recover millions of dollars in losses over the years. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510
www.zlk.com
Logo - http://photos.prnewswire.com/prnh/20120409/MM84375LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/update--monday-deadline-levi--korsinsky-llp-notifies-investors-of-class-action-against-aeterna-zentaris-inc-and-its-board-of-directors-and-a-lead-plaintiff-deadline-of-january-12-2015----aezs-300018515.html
SOURCE Levi & Korsinsky, LLP
Copyright 2015 PR Newswire
1 Year Aeterna Zentaris Chart |
1 Month Aeterna Zentaris Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions